PLSE
Hot AirPulse Biosciences, Inc. · Healthcare · United States · $3.8B cap · $23.0M/day traded
$56.98 +3.4% · close 11 Nov · scored 11 Nov
Score down 1.4 since 10 Nov.
Hot Air: Strong momentum and nothing else: weak business, rich price.
As of 11 Nov 2026, the MoatMap Score for Pulse Biosciences, Inc. (PLSE) is 28/100, ranked against 25,000+ stocks in 38 markets (Quality 22, Value 19, Momentum 75, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT PULSE BIOSCIENCES, INC.
Read
Pulse Biosciences is a novel medical technology company pioneering the development of its proprietary Nano-Pulse Stimulation (NPS) technology for cellular tissue clearance. The company's CellFX system delivers nanosecond electrical pulses to non-thermally clear targeted cells while sparing surrounding non-cellular tissue. Its competitive moat is anchored by a robust intellectual property portfolio and a unique, high-margin consumable business model in dermatology and other surgical applications.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.7M | 0 | 0 | 0.3M | -20.6% | 1.5M | 1.8M | 5.7M | 301.8% |
| EPS | -1.69 | -0.85 | -0.92 | -1.08 | — | -1.21 | -1.02 | -1.13 | — |
| Shares | 37.9M | 56.1M | 65.9M | 67.8M | +79.2% | 73.5M | — | — | — |
| Debt | 76.0M | 9.1M | 8.9M | 7.5M | -53.7% | 6.4M | — | — | — |
| Equity | -2.2M | 44.4M | 114.9M | 80.7M | 34.8% | — | — | — | — |
| Op CF | -47.0M | -33.0M | -36.3M | -54.1M | — | -63.3M | — | — | — |
| Inv CF | -0.4M | -0.1M | -0.1M | -0.3M | — | — | — | — | — |
| Fin CF | 79.9M | 16.4M | 110.1M | 17.2M | — | — | — | — | — |
Above its 200-day average and 6% below its 52-week high.
Swung more than 92% of stocks we rank over the past year (volatility 89% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PLSE are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| PLSE | Pulse Biosciences, Inc.(you) | $3.8B | 28 |
| KMTS | Kestra Medical Technologies, Ltd. | $1.7B | 29 |
| STAA | STAAR Surgical Company | $1.1B | 31 |
| WRBY | Warby Parker Inc. | $3.2B | 54 |
| AZTA | Azenta, Inc. | $1.6B | 45 |
| LMAT | LeMaitre Vascular, Inc. | $1.9B | 50 |
| XRAY | DENTSPLY SIRONA Inc. | $1.9B | 51 |
| MMED | MiniMed Group, Inc. | $5.2B | 59 |
| ATRC | AtriCure, Inc. | $3.0B | 61 |
| ANGO | AngioDynamics, Inc. | $520M | 34 |
Peer medians: ROE -30.0% · P/E 25.9x · Gross margin 63.3%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.